Want to see CH:SDZ full AI Analyst Report?

Sandoz Group Ltd (SDZ) Price & Analysis

38 Followers

SDZ Stock Chart & Stats

CHF70.66

CHF0.10(0.16%)

At close: Jul 27 4:00 PM EDT

CHF70.66

CHF0.10(0.16%)

Day’s Range― - ―

52-Week RangeCHF48.15 - CHF83.38

Previous CloseN/A

Volume78.14K

Average Volume (3M)1.65M

Market Cap

CHF36.24B

Enterprise ValueCHF36.05B

Total Cash (Recent Filing)CHF1.25B

Total Debt (Recent Filing)CHF6.22B

Price to Earnings (P/E)66.8

Beta0.96

Next Earnings

Feb 17, 2027

EPS Estimate

1.88

Next Dividend Ex-DateN/A

Dividend Yield0.97%

Share Statistics

EPS (TTM)1.49

Shares Outstanding440,000,000

10 Day Avg. Volume972,126

30 Day Avg. Volume1,646,177

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)3.35

Price to Sales (P/S)2.82

P/FCF Ratio38.83

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF77.43

Price Target Upside9.58% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)4.05

Revenue Forecast (FY)CHF12.08B

Bulls Say, Bears Say

Bulls Say

2025 Profitability RecoveryThe 2025 recovery shows renewed operating traction, while consistently strong gross margins indicate resilient product economics. If revenue expansion and margin discipline persist, Sandoz should have greater capacity to reinvest in launches, regulatory filings, and manufacturing scale over the coming quarters.

Improved Cash GenerationThe sharp improvement in operating and free cash flow strengthens Sandoz’s ability to fund product development, capital investment, debt service, and shareholder returns internally. Positive cash generation also gives the company more flexibility to pursue biosimilar growth without relying entirely on external financing.

Broad Global Generics And Biosimilars PlatformA broad portfolio spanning small-molecule generics and biosimilars creates multiple avenues for durable revenue generation after reference-product exclusivity expires. Global distribution across pharmacies, hospitals, and healthcare systems can support scale, portfolio diversification, and recurring demand for essential medicines.

Bears Say

Earnings VolatilityThe uneven earnings record makes the durability of the 2025 recovery less certain and complicates planning for investment and capital allocation. Volatile operating profitability may reflect changing product mix, launches, pricing, or costs, creating greater risk that future results will not track the latest rebound.

Variable Free Cash FlowLarge year-to-year swings in free cash flow reduce confidence in the consistency of internally generated funding. Even with strong 2025 cash generation, sensitivity to working-capital or investment cycles could constrain spending on growth initiatives or debt reduction during weaker periods.

Rising Absolute DebtModerate leverage is manageable, but rising absolute debt can increase fixed financial obligations and reduce flexibility if earnings or cash flow weaken. It also places more importance on sustaining the recent profitability recovery, because weaker operating performance could make balance-sheet improvement slower.

Sandoz Group Ltd News

Sandoz price target raised to CHF 60 from CHF 55 at Morgan Stanley

Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Sandoz (SDZNY) to CHF 60 from CHF...

22d ago

Sandoz Lifts Margin Guidance as Biosimilars Drive Q3 Growth

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an announcement. Sandoz reported third-quarter net sales growth of 5%...

1h ago

Sandoz boosts European biosimilar capacity with new Slovenian plant

Sandoz Group Ltd ( ($CH:SDZ) ) has provided an update. Sandoz has opened a high-tech, high-volume biosimilar drug...

29d ago

mAbxience, Sandoz sign collaboration agreement for biosimilar access

mAbxience, a majority-owned company of Fresenius (FSNUY) with partial ownership from Insud Pharma; and Sandoz (SDZNY) announced a...

1M ago

Sandoz joins mAbxience to develop emicizumab biosimilar and expand haemophilia pipeline

An announcement from Sandoz Group Ltd ( ($CH:SDZ) ) is now available. Sandoz has entered a licensing, development,...

1M ago

Sandoz Wins Canadian Approval for Generic Semaglutide, Targeting Growing GLP-1 Market

An announcement from Sandoz Group Ltd ( ($CH:SDZ) ) is now available. Sandoz has secured Health Canada marketing...

1M ago

Sandoz price target raised to CHF 72 from CHF 66 at Berenberg

Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 72 from CHF 66 and keeps a...

2M ago

Sandoz invests USD 300 million in new Slovenian biosimilar facility to boost capacity

Sandoz Group Ltd ( ($CH:SDZ) ) has provided an announcement. Sandoz plans to invest around USD 300 million...

2M ago

Sandoz Unveils Bio100 Plan to Drive Golden Decade of Biosimilars

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an announcement. Sandoz used its Capital Markets Day in London...

2M ago

Sandoz initiated with a Buy at Erste Group

Erste Group analyst Hans Engel initiated coverage of Sandoz (SDZNY) with a Buy rating. The company’s product pipeline...

2M ago

Sandoz expands biosimilar pipeline with major Henlius collaboration

Sandoz Group Ltd ( ($CH:SDZ) ) has issued an announcement. Sandoz has signed a major development, manufacturing and...

2M ago

Sandoz price target raised to CHF 80 from CHF 75 at JPMorgan

JPMorgan raised the firm’s price target on Sandoz (SDZNY) to CHF 80 from CHF 75 and keeps an...

3M ago

Sandoz H1 2026 profits surge as biosimilars drive growth and strategy

Sandoz Group Ltd ( ($CH:SDZ) ) just unveiled an update. Sandoz reported first-half 2026 net sales of USD...

3M ago

Sandoz takes steps to resolve U.S. generic medicine pricing litigation

Sandoz (SDZNY) announces several steps to further resolve the US Generic Drug Antitrust Pricing Litigation. Sandoz and its...

3M ago

SDZ FAQ

What was Sandoz Group Ltd’s price range in the past 12 months?

Sandoz Group Ltd lowest stock price was CHF48.15 and its highest was CHF83.38 in the past 12 months.

What is Sandoz Group Ltd’s market cap?

Sandoz Group Ltd’s market cap is CHF36.24B.

When is Sandoz Group Ltd’s upcoming earnings report date?

Sandoz Group Ltd’s upcoming earnings report date is Feb 17, 2027 which is in 112 days.

How were Sandoz Group Ltd’s earnings last quarter?

Sandoz Group Ltd released its earnings results on Aug 05, 2026. The company reported CHF1.423 earnings per share for the quarter, missing the consensus estimate of CHF1.49 by -CHF0.067.

Is Sandoz Group Ltd overvalued?

According to Wall Street analysts Sandoz Group Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sandoz Group Ltd pay dividends?

Sandoz Group Ltd pays a Annually dividend of CHF0.8 which represents an annual dividend yield of 0.97%. See more information on Sandoz Group Ltd dividends here

What is Sandoz Group Ltd’s EPS estimate?

Sandoz Group Ltd’s EPS estimate is 1.88.

How many shares outstanding does Sandoz Group Ltd have?

Sandoz Group Ltd has 440,000,000 shares outstanding.

What happened to Sandoz Group Ltd’s price movement after its last earnings report?

Sandoz Group Ltd reported an EPS of CHF1.423 in its last earnings report, missing expectations of CHF1.49. Following the earnings report the stock price went up 6.038%.

Which hedge fund is a major shareholder of Sandoz Group Ltd?

Currently, no hedge funds are holding shares in CH:SDZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sandoz Group Ltd

Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.

Sandoz Group Ltd (SDZ) Earnings & Revenues

Historic Earnings Reports

SDZ Company Deck

SDZ Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture with strong sales growth, particularly in the biosimilars segment and North American market recovery. However, the financial performance was impacted by negative free cash flow, a decline in core EBITDA margin, significant restructuring, and legal costs.View all CH:SDZ earnings summaries

SDZ Stock 12 Month Forecast

Average Price Target

CHF77.43

▲(9.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"CHF43","56":"CHF56","69":"CHF69","82":"CHF82","95":"CHF95"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF94.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.42857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF77.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,56,69,82,95],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.42,70.3876923076923,72.35538461538462,74.32307692307693,76.29076923076923,78.25846153846155,80.22615384615385,82.19384615384615,84.16153846153847,86.12923076923077,88.09692307692308,90.0646153846154,92.0323076923077,{"y":94,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.42,69.11296703296703,69.80593406593407,70.4989010989011,71.19186813186813,71.88483516483517,72.5778021978022,73.27076923076923,73.96373626373627,74.6567032967033,75.34967032967033,76.04263736263736,76.7356043956044,{"y":77.42857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.42,67.77230769230769,67.12461538461538,66.47692307692307,65.82923076923078,65.18153846153847,64.53384615384616,63.886153846153846,63.238461538461536,62.59076923076923,61.94307692307692,61.29538461538462,60.64769230769231,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.173,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.857,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.058,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.145,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.524,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.788,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.76,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.88,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.42,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >